Cabergoline Effect on Blood Sugar in Type 2 Diabetics

Diabetes Type 2 Clinical Trial

Official title:

Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01459601
• Other study ID #: CabergolinDM
• Status: Not yet recruiting
• Phase: N/A
• First received: October 24, 2011
• Last updated: October 24, 2011
• Start date: January 2012
• Est. completion date: February 2012

Study information

• Verified date: October 2011
• Source: Mashhad University of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: Iran: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: February 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Type 2 diabetes

• HbA1C>7

Exclusion Criteria:

• HbA1C>10

• Psychiatric disorders

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Diabetes Type 2

Intervention

Drug:
• Cabergoline
0,5mg per week

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Mashhad University of Medical Sciences

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	FBS (fasting blood sugar)		30days	No
Secondary	HbA1C		30days	No